To our knowledge, this is the first prospective clinical trial assessing the utility of a response guided therapy approach based on mathematical modeling to individualize treatment duration with DAAs in CHC. Model-based decisions led to treatment shortening in 38% of patients and to an overall time saving of 14% in treatment duration. Implementation of the model was safe and did not compromise treatment efficacy.
Implementation of an RGT approach for treatment of HCV on a larger scale could lead to a significant reduction in treatment cost. This may improve access to HCV care especially in resource limited settings and facilitate the goal of HCV elimination.
Read Full Publication Here!